Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Hudson Valley Hematology and Oncology Associates/New York Medical College
mi
from
Hawthorne, NY
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Hudson Valley Hematology and Oncology Associates/New York Medical College
mi
from
Hawthorne, NY
Click here to add this to my saved trials
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Shands HealthCare & University of Florida
mi
from
Gainesville, FL
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Shands HealthCare & University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center - Adults
mi
from
New York, NY
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center - Adults
mi
from
New York, NY
Click here to add this to my saved trials
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Ohio State Medical Center, James Cancer Center
mi
from
Columbus, OH
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Ohio State Medical Center, James Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center Bone Marrow Transplant Program
mi
from
Richmond, VA
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center Bone Marrow Transplant Program
mi
from
Richmond, VA
Click here to add this to my saved trials
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Froedtert Memorial Lutheran Hospital
mi
from
Milwaukee, WI
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Froedtert Memorial Lutheran Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Study of Concurrent Decitabine in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Study of Concurrent Decitabine in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Who Have Achieved a Complete Hematologic Remission, Complete Cytogenetic Remission, and Major Molecular Remission, But Not a Complete Molecular Remission on a Tyrosine Kinase Inhibitor Alone.
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Who Have Achieved a Complete Hematologic Remission, Complete Cytogenetic Remission, and Major Molecular Remission, But Not a Complete Molecular Remission on a Tyrosine Kinase Inhibitor Alone.
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Who Have Achieved a Complete Hematologic Remission, Complete Cytogenetic Remission, and Major Molecular Remission, But Not a Complete Molecular Remission on a Tyrosine Kinase Inhibitor Alone.
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Who Have Achieved a Complete Hematologic Remission, Complete Cytogenetic Remission, and Major Molecular Remission, But Not a Complete Molecular Remission on a Tyrosine Kinase Inhibitor Alone.
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Alabama /ID# 151405
mi
from
Birmingham, AL
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Alabama /ID# 151405
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences /ID# 151399
mi
from
Little Rock, AR
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences /ID# 151399
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital /ID# 161710
mi
from
Atlanta, GA
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital /ID# 161710
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Chicago /ID# 151395
mi
from
Chicago, IL
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Chicago /ID# 151395
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Kentucky Chandler Medical Center /ID# 151407
mi
from
Lexington, KY
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Kentucky Chandler Medical Center /ID# 151407
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Duke University Medical Center /ID# 162062
mi
from
Durham, NC
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Duke University Medical Center /ID# 162062
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania /ID# 151768
mi
from
Philadelphia, PA
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania /ID# 151768
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Utah /ID# 151397
mi
from
Salt Lake City, UT
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Utah /ID# 151397
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
VA Puget Sound Healthcare Syst /ID# 155369
mi
from
Seattle, WA
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
VA Puget Sound Healthcare Syst /ID# 155369
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Auxilio Mutuo Cancer Center /ID# 157853
mi
from
San Juan,
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Auxilio Mutuo Cancer Center /ID# 157853
mi
from
San Juan,
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
St Jude Medical Center / St Joseph Health /ID# 210183
mi
from
Fullerton, CA
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
St Jude Medical Center / St Joseph Health /ID# 210183
mi
from
Fullerton, CA
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Marin Cancer Care /ID# 210408
mi
from
Greenbrae, CA
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Marin Cancer Care /ID# 210408
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center - West Hollywood /ID# 210819
mi
from
West Hollywood, CA
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center - West Hollywood /ID# 210819
mi
from
West Hollywood, CA
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Univ Maryland School Medicine /ID# 159721
mi
from
Baltimore, MD
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Univ Maryland School Medicine /ID# 159721
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Gundersen Health System /ID# 210807
mi
from
La Crosse, WI
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Gundersen Health System /ID# 210807
mi
from
La Crosse, WI
Click here to add this to my saved trials
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Aurora Health Care, Aurora Cancer Center /ID# 209612
mi
from
Wauwatosa, WI
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Aurora Health Care, Aurora Cancer Center /ID# 209612
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Winship Cancer Institute Emory University School of Medicine
mi
from
Atlanta, GA
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Winship Cancer Institute Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Charles A. Sammons Cancer Center at Baylor University Medical Center
mi
from
Dallas, TX
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Charles A. Sammons Cancer Center at Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
John Theurer Cancer Center-Hackensack Meridian Health
mi
from
Hackensack, NJ
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
John Theurer Cancer Center-Hackensack Meridian Health
mi
from
Hackensack, NJ
Click here to add this to my saved trials
PET (Positron Emission Tomography) Imaging Studies With NIS Reporter
First In-human PET Imaging Studies With NIS Reporter [18F]BF4
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
PET (Positron Emission Tomography) Imaging Studies With NIS Reporter
First In-human PET Imaging Studies With NIS Reporter [18F]BF4
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated:  12/31/1969
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated: 12/31/1969
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
High Dose Carfilzomib for Newly Diagnosed Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
Click here to add this to my saved trials